View Older Stories View More Recent Stories
-
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
-
ClearPoint Neuro completes IRRAS acquisition for $5 million plus shares
-
ClearPoint Neuro Completes Acquisition of IRRAS
-
ClearPoint Neuro, Inc. (CLPT) Misses Q3 EPS by 3c
-
ClearPoint Neuro Reports Third Quarter 2025 Results
-
ClearPoint Neuro to acquire IRRAS in $5M cash and stock deal
-
ClearPoint Neuro Announces Agreement to Acquire IRRAS
-
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
-
ClearPoint Neuro reports brain tumor laser therapy study results
-
ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles
-
ClearPoint Neuro gains regulatory approvals in Canada, Hong Kong, Taiwan
-
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
-
ClearPoint Neuro develops robotic neuro-navigation system prototype
-
ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System
-
ClearPoint Neuro names Dr. Paul Larson as chief medical officer
-
ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer
-
ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners
-
ClearPoint Neuro, Inc. (CLPT) Misses Q2 EPS by 1c
-
ClearPoint Neuro Reports Second Quarter 2025 Results
-
ClearPoint Neuro delivers first commercial gene therapy to US brains
-
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio
-
ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025
-
ClearPoint Neuro Reports First Quarter 2025 Results
-
ClearPoint Neuro Inc. (CLPT) announces investment up to $105 million by Oberland Capital
-
ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing
-
ClearPoint Neuro Inc. (CLPT) Announces FDA Submission to Expand the Labeling of ClearPoint Prism to Include 1.5 T MRI
-
ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI
-
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025
-
ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 – Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room
-
Clearpoint Neuro Inc. (CLPT) PT Raised to $25 at Stifel
-
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
-
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
-
ClearPoint Neuro Inc.'s SmartFlow Neuro Cannula receives approval from EU MDR
-
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula
-
Stifel Reiterates Buy Rating on Clearpoint Neuro Inc. (CLPT)
-
ClearPoint Neuro Inc. (CLPT) Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
-
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
-
Clearpoint Neuro Inc. (CLPT) PT Raised to $30 at Lake Street Capital Markets
-
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
-
ClearPoint Neuro, Inc. (CLPT) Misses Q3 EPS by 1c
-
ClearPoint Neuro Reports Third Quarter 2024 Results
-
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
-
Clearpoint Neuro Inc. (CLPT) PT Raised to $15 at Lake Street Capital Markets
-
ClearPoint Neuro Inc. (CLPT) Announces Early Repayment of $10 Million Note
